![]() |
| Alex Kelly |
Precision BioSciences, Inc., a clinical-stage biotechnology company, has appointed Alex Kelly chief corporate affairs officer.
Kelly comes to the company from Allergan, where he was executive vice president, corporate affairs and chief communications officer, as well as president of The Allergan Foundation. In those roles, he developed internal and external messaging and supported Allergan’s recent merger with AbbVie.
Kelly has also served as senior VP, chief integration officer at Actavis and senior VP, chief communications officer, public affairs and investor relations at Forest Labs.
In his new role, he will join the senior leadership team and oversee all investor relations and corporate communications. "Alex brings valuable and meaningful experience leading corporate affairs for some of the most successful healthcare companies in the industry,” said Precision CEO Matt Kane.


FINN Partners has named Jessica Lise managing partner & New York health group lead to succeed Tom Jones, who is exiting after nearly eight years to relaunch his own firm.
The opportunities that GEO can provide for healthcare communicators will be the subject of a Nov. 17 webinar from Padilla.
Science is a journey of discovery, not a destination. The recent clinical trial disappointments involving Novartis and Novo Nordisk offer an important opportunity to reflect on the nature of scientific progress.
To make sure that the messages an annual meeting is supposed to deliver connect with their audiences, focus on the big story behind the complex data.
It’s not enough to simply be a good storyteller. Communicators now need to be explainers—making a range of complex subjects understandable to consumers.



